tiprankstipranks
Advertisement
Advertisement

TScan Therapeutics expects cash to fund operations into Q1 of 2027

Cash, cash equivalents, and marketable securities as of June 30, 2025, were $218.0 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into the first quarter of 2027.

Meet Samuel – Your Personal Investing Prophet

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1